Does sermorelin acetate affect in vitro fertilization (IVF), specifically the embryo transfer stage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Evidence That Sermorelin Acetate Affects IVF or Embryo Transfer

There is no evidence that sermorelin acetate has any role in or effect on in vitro fertilization (IVF) procedures, including the embryo transfer stage. The available FDA drug labeling for sermorelin acetate indicates it is for external use only and provides no indication for use in reproductive medicine 1.

What Sermorelin Acetate Actually Is

Sermorelin acetate is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the natural 44-amino acid peptide 2. Its established medical uses are:

  • Diagnostic testing for growth hormone deficiency in children 3
  • Treatment of idiopathic growth hormone deficiency in prepubertal children 3
  • It works by stimulating the pituitary gland to release endogenous growth hormone

The peptide has a very short half-life (10-20 minutes in humans) and undergoes rapid renal clearance 2. Importantly, sermorelin does not cross the placenta - studies in pregnant women at term showed that GRF concentrations were undetectable in cord blood despite being readily detectable in maternal serum 4.

Why This Question May Arise: Growth Hormone in IVF

The confusion likely stems from the use of growth hormone (GH) itself - not sermorelin - as an adjuvant therapy in some IVF protocols. However, even this practice lacks evidence:

  • The largest randomized controlled trial of adjuvant GH therapy in IVF (288 patients) found no benefit for clinical pregnancy rates, implantation rates, or number of retrieved oocytes 5
  • The study concluded: "Empiric adjuvant GH therapy in GnRH antagonist cycles does not improve IVF stimulation results or reproductive outcomes" 5

Current Evidence-Based IVF Practice

According to the 2024 ESHRE guidelines on embryo transfer, the key factors that actually matter for IVF outcomes are 6:

  • Number of embryos transferred (single embryo transfer strongly recommended to minimize multiple pregnancy risks)
  • Embryo quality and developmental stage
  • Patient age and ovarian reserve
  • Number of previous failed cycles
  • Endometrial preparation

Sermorelin is not mentioned anywhere in current IVF guidelines or evidence-based protocols.

Common Pitfall to Avoid

Do not confuse sermorelin acetate with growth hormone itself, and do not assume that because growth hormone has been studied (albeit unsuccessfully) in IVF that sermorelin would have similar applications. Sermorelin's mechanism is to stimulate endogenous GH release, but even direct GH supplementation has failed to show benefit in the general IVF population 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.